Effect of a Remotely Delivered Weight Loss Intervention in Early-Stage Breast Cancer: Randomized Controlled Trial
Limited evidence exists on the effects of weight loss on chronic disease risk and patient-reported outcomes in breast cancer survivors. Breast cancer survivors (stage I–III; body mass index 25–45 kg/m<sup>2</sup>) were randomized to a 12-month, remotely delivered (22 telephone calls, mai...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2023d5e75de347d2836babf2431922f2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Limited evidence exists on the effects of weight loss on chronic disease risk and patient-reported outcomes in breast cancer survivors. Breast cancer survivors (stage I–III; body mass index 25–45 kg/m<sup>2</sup>) were randomized to a 12-month, remotely delivered (22 telephone calls, mailed material, optional text messages) weight loss (diet and physical activity) intervention (<i>n</i> = 79) or usual care (<i>n</i> = 80). Weight loss (primary outcome), body composition, metabolic syndrome risk score and components, quality of life, fatigue, musculoskeletal pain, menopausal symptoms, fear of recurrence, and body image were assessed at baseline, 6 months, 12 months (primary endpoint), and 18 months. Participants were 55 ± 9 years and 10.7 ± 5.0 months post-diagnosis; retention was 81.8% (12 months) and 80.5% (18 months). At 12-months, intervention participants had significantly greater improvements in weight (−4.5% [95%CI: −6.5, −2.5]; <i>p</i> < 0.001), fat mass (−3.3 kg [−4.8, −1.9]; <i>p</i> < 0.001), metabolic syndrome risk score (−0.19 [−0.32, −0.05]; <i>p</i> = 0.006), waist circumference (−3.2 cm [−5.5, −0.9]; <i>p</i> = 0.007), fasting plasma glucose (−0.23 mmol/L [−0.44, −0.02]; <i>p</i> = 0.032), physical quality of life (2.7 [0.7, 4.6]; <i>p</i> = 0.007; Cohen’s effect size (<i>d</i>) = 0.40), musculoskeletal pain (−0.5 [−0.8, −0.2]; <i>p</i> = 0.003; <i>d</i> = 0.49), and body image (−0.2 [−0.4, −0.0]; <i>p</i> = 0.030; <i>d</i> = 0.31) than usual care. At 18 months, effects on weight, adiposity, and metabolic syndrome risk scores were sustained; however, significant reductions in lean mass were observed (−1.1 kg [−1.7, −0.4]; <i>p</i> < 0.001). This intervention led to sustained improvements in adiposity and metabolic syndrome risk. |
|---|